Search

Lamellar Keratoplasty Using Acellular Bioengineering Cornea (BioCorneaVet TM) for the Treatment of Feline Corneal Sequestrum: A Retrospective Study of 62 Eyes (2018-2021) OCT showed that the epithelium and lacrimal film were intact, both the graft and cornea remained stable, the corneal edema subsided, and the transition between donor graft and recipient corneal bed could not be seen at the third month post-surgery (Figure 6C). Furthermore, no involvement of conjunctival tissues that would be used in CCT and conjunctival grafts surgery when we only used BioCorneaVet SP TM sp in keratoplasty would not only protect the cornea and surrounding tissues from secondary damage, but also improve the transparency of the cornea post-surgery. A number of surgical methods and materials are currently available for the treatment of such a disorder, including lamellar keratectomy combined with conjunctival grafts [[1]], porcine small intestinal submucosa (BIOSIS) transplantation [[6]], porcine bladder ACell SP ® sp tissue graft transplantation [[8]], corneo-conjunctival transposition (CCT) [[2], [9]], bovine pericardium graft [[10]], cyanoacrylate adhesive [[11]], amniotic membrane transplantation [[12]], and homograft or xenograft corneal transplantation [[13], [15]]. [Extracted from the article]

To retrospectively evaluate the effectiveness and outcome of lamellar keratoplasty using acellular bioengineering cornea (BioCorneaVet TM ) for the treatment of feline corneal sequestrum (FCS). The medical records of cats diagnosed with FCS that underwent lamellar keratoplasty with BioCorneaVet TM between 2018 and 2021 with a minimum of 3 months of follow-up were reviewed. Follow-up examinations were performed weekly for 3 months, and then optical coherence tomography (OCT) examination was performed on select patients at 0, 3, 6, and 12 months post-operatively. A total of 61 cats (30 left eyes and 32 right eyes) were included. The Persian breed was overrepresented, 48/61 (78.69%). Four different thicknesses of acellular bioengineering cornea were used (200, 300, 400, or 450 microns), and the mean graft size was 8.23 mm (range, 5.00-12.00 mm). Minor complications were composed of partial dehiscence, and protrusion of the graft occurred in 7/62 eyes (11.29%). The median postoperative follow-up was 12.00 months (range, 3-41 months). A good visual outcome was achieved in 60/62 eyes (96.77%), and a mild to moderate corneal opacification occurred in 2/62 (3.23%). No recurrence of corneal sequestrum was observed. From the results, lamellar keratoplasty using acellular bioengineering cornea (BioCorneaVet TM ) is an effective treatment for FCS, providing a good tectonic support and natural collagen framework, and resulting in satisfactory visual and cosmetic effects.